OTCMKTS:RGDXQ - Response Genetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0013 0.00 (0.00 %) (As of 02/20/2019 10:37 AM ET)Previous Close$0.0013Today's Range$0.0013 - $0.001352-Week Range$0.0003 - $0.0074Volume1,300 shsAverage Volume10,587 shsMarket Capitalization$50,427.00P/E RatioN/ADividend YieldN/ABeta0.16 ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. Receive RGDXQ News and Ratings via Email Sign-up to receive the latest news and ratings for RGDXQ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:RGDXQ Previous SymbolNASDAQ:RGDX CUSIPN/A Webwww.responsegenetics.com Phone323-224-3900Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares38,790,000Market Cap$50,427.00 OptionableNot Optionable Response Genetics (OTCMKTS:RGDXQ) Frequently Asked Questions What is Response Genetics' stock symbol? Response Genetics trades on the OTCMKTS under the ticker symbol "RGDXQ." Has Response Genetics been receiving favorable news coverage? Media coverage about RGDXQ stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Response Genetics earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. Who are some of Response Genetics' key competitors? Some companies that are related to Response Genetics include IDEXX Laboratories (IDXX), IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Quotient (QTNT), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX) and Trinity Biotech (TRIB). Who are Response Genetics' key executives? Response Genetics' management team includes the folowing people: Thomas A. Bologna, Chairman of the Board, Chief Executive Officer (Age 66)Kevin Roy Harris, Chief Financial Officer, Vice President (Age 47)Adanech Getachew, General Counsel (Age 37)Kirk K. Calhoun, Lead Independent Director (Age 73)Michael Serruya, Director (Age 51)Sam Chawla, Independent Director (Age 41)David R Schreiber, Independent Director (Age 55)Richard A. van den Broek, Independent Director (Age 49) How do I buy shares of Response Genetics? Shares of RGDXQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Response Genetics' stock price today? One share of RGDXQ stock can currently be purchased for approximately $0.0013. How big of a company is Response Genetics? Response Genetics has a market capitalization of $50,427.00. What is Response Genetics' official website? The official website for Response Genetics is http://www.responsegenetics.com. How can I contact Response Genetics? Response Genetics' mailing address is 1640 MARENGO ST 7TH FLOOR, LOS ANGELES CA, 90033. The medical research company can be reached via phone at 323-224-3900 or via email at [email protected] MarketBeat Community Rating for Response Genetics (OTCMKTS RGDXQ)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 47 (Vote Outperform)Underperform Votes: 47 (Vote Underperform)Total Votes: 94MarketBeat's community ratings are surveys of what our community members think about Response Genetics and other stocks. Vote "Outperform" if you believe RGDXQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGDXQ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: How prevalent are 12b-1 fees?